Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iodine-131-labeled silk fibroin microspheres
- Development stage
- Preclinical
- Lead developer
- Sichuan University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Drug Delivery Systems
- Administration
- Intra-arterial
01
Overview
**Iodine-131-labeled silk fibroin microspheres** are biodegradable radiopharmaceutical microspheres developed experimentally for transarterial radioembolization of hepatocellular carcinoma. The product consists of genipin-crosslinked silk fibroin microspheres, derived from silkworm-cocoon fibroin and radiolabeled with iodine-131 using chloramine-T chemistry. Following intra-arterial hepatic administration, the approximately 11 micrometer microspheres embolize tumor-feeding hepatic arterial vessels while iodine-131 delivers localized internal radiation to liver tumor tissue. In a rat hepatocellular carcinoma model, the material showed favorable tumor-growth inhibition, biodistribution, biodegradability, hemocompatibility, and low cytotoxicity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35507826/))
- Other names
- 131I-labeled silk fibroin microspheres131I-SFMsiodine-131-labeled silk fibroin microspheresiodine131-labeled silk fibroin microspheresiodine 131-labeled silk fibroin microspheres
02
Targets
DNA
Beyond the preview
Go deeper on iodine-131-labeled silk fibroin microspheres.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iodine-131-labeled silk fibroin microspheres.